Pharmacokinetics and Excretion of Hydroxysafflor Yellow A, a Potent Neuroprotective Agent from Safflower, in Rats and Dogs

Abstract

Studies were conducted to characterize the pharmacokinetics and excretion of hydroxysafflor yellow A (HSYA) in rats and dogs after administration by intravenous injection or infusion. Plasma, urine, feces and bile concentrations of HSYA were measured using five validated mild HPLC methods. Linear pharmacokinetics of HSYA after the intravenous administrations were found at doses ranging from 3 to 24 mg/kg in rats and from 6 to 24 mg/kg in dogs. At a dose of 3 mg/kg, HSYA in urine, feces and bile was determined. For 48 h after dosing, the amount of urinary excretion accounted for 52.6 ± 17.9 % (range: 31.1 - 78.7 %, n = 6) of the dose, and the amount of fecal amount accounted for 8.4 ± 5.3 % (range 1.7 - 16.4 %, n = 6) of the dose. Biliary excretion amount accounted for 1.4 ± 1.0 % (range 0.4 - 2.9 %; n = 6) of the dose for 24 h after dosing. Percent plasma protein binding of HSYA ranged from 48.0 to 54.6 % at 72 h. In summary, five mild HPLC methods for the determinations of HSYA in rat plasma, urine, feces, bile and dog plasma have been developed and successfully applied to preclinical pharmacokinetics and excretion of HSYA in rats and dogs. The results of excretion studies indicated that HSYA was rapidly excreted as unchanged drug in the urine. In view of previous pharmacological work, the concentration-dependent neuroprotective effect of HSYA in rats was defined.

Composite - Carthamus tinctorius L. - hydroxysafflor yellow A - pharmacokinetics - excretion

References

• 1 The State Pharmacopoeia Commission of C hina. Pharmacopoeia of the People’s Republic of China, Part I. Beijing; Chemical Industry Press 2000: p 119
• 2 Kohei K, Takashi T, Katusura S, Hisatomo T, Takeshi M, Toshikatsu M. Quinochalcones and flavonoids from fresh florets in different cultivars of Carthamus tinctorius L.  Biosci Biotechnol Biochem. 2000;  64 1588-99
• 3 Romano C, Price M, Bai H Y, Olney J W. Neuroprotectants in Honghua: glucose attenuates retinal ischemic damage.  Invest Ophthalmol Vis Sci. 1993;  34 72-80
• 4 Zang B X, Jin M, Si N, Zhang Y, Wu W, Piao Y Z. Antagonistic effect of hydroxysafflor yellow A on the platelet activating factor receptor.  Acta Pharm Sin. 2002;  37 696-9
• 5 Zhu H B, Wang Z H, Ma C J, Tian J W, Fu F H, Li C L. et al . Neuroprotective effect of hydroxysafflor yellow A: in vivo and in vitro studies.  Planta Med. 2003;  69 429-33
• 6 Liu Y Q, Li K, Bi K S. Pharmacokinetics of safflower yellow A in rats in vivo .  Chin Tradit Herbal Drugs. 2003;  34 725-7
• 7 Xiong Q M, Min Y, Liu Y, Pan M F, Liu Q H. Pharmacokinetics of hydroxysafflor yellow A in rats.  Chin J Pharm. 2004;  35 228-30
• 8 Jin M, Zang B X, Li J R, Wang J F. Studies on the heating stability of hydroxysafflor yellow A.  Chin J Chin Mater Med. 2003;  28 1197-8
• 9 Meselhy M R, Kadota S, Momose Y, Hatakeyama N, Kusai A, Hattori M. et al . Two new quinochalcone yellow pigments from Carthamus tinctorius and Ca²⁺ antagonistic activity of tinctormine.  Chem Pharm Bull. 1993;  41 1796-802
• 10 Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics. New York; Marcel Dekker Inc 1982: p 409-17
• 11 Shuyun X u, Rulian B ian, Xiu C hen. Methodologies of pharmacological experiments. Beijing; People’s Medical Publishing House (PMPH) 2002: p 708-9